MedTrace Logo

Screening for Malnutrition in Obese Patients

NCT06626360 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2024-11-08

No results posted yet for this study

Summary

More than half of the Dutch population is overweight or obese, which is associated with an increased risk of COVID-19 and worse outcomes during a COVID-19 infection. In addition, malnutrition and loss of muscle mass are often reported with COVID-19, as well as with cancer and other diseases. Malnutrition and overweight or obesity can coexist, even within the same individual. It is still unclear which mechanisms contribute to the worse outcomes of COVID-19 and other diseases in case of overweight, malnutrition, and a combination of both. The aim of this study is to identify which parameters are associated with worse disease outcomes through literature research and database research (COVID-19 and cancer, more than 150.000 participants). In addition, a clinical study will be conducted aiming to develop a simple screening tool for the recognition of the coexistence of malnutrition and overweight or obesity in clinical practice.

Conditions

  • Overweight and Obese Adults
  • Malnutrition or Risk of Malnutrition

Sponsors & Collaborators

  • Amsterdam University of Applied Sciences

    collaborator OTHER

  • National Institute for Public Health and the Environment (RIVM)

    collaborator OTHER_GOV

  • Erasmus Medical Center

    collaborator OTHER

  • Wageningen University and Research

    collaborator OTHER

  • Gelderse Vallei Hospital

    collaborator OTHER

  • Amsterdam UMC, location VUmc

    collaborator OTHER

  • Amsterdam UMC, location AMC

    collaborator OTHER

  • HAN University of Applied Sciences

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-02
Primary Completion
2025-04-30
Completion
2025-08-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06626360 on ClinicalTrials.gov